Navigation Links
Idenix Announces Data Presentations from Three HCV Discovery and Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL)
Date:3/18/2009

CAMBRIDGE, Mass., March 18 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that four abstracts from the company's hepatitis C antiviral discovery and development programs have been accepted for presentation at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL, April 22-26, 2009 in Copenhagen, Denmark). Full abstracts can now be viewed at the EASL website at www.easl.ch.

The four accepted abstracts are as follows:

  • ANTIVIRAL ACTIVITY OF THE LIVER-TARGETED NUCLEOTIDE HCV POLYMERASE INHIBITOR IDX184 CORRELATES WITH TROUGH SERUM LEVELS OF THE NUCLEOSIDE METABOLITE IN HCV-INFECTED CHIMPANZEES - Abstract #583; Oral presentation; Parallel session entitled: Hepatitis C Virus Drug Development II; Session date: Friday, April 24, 2009; Session time: 16:00 - 18:00

  • IDX184, A LIVER-TARGETED NUCLEOTIDE HCV POLYMERASE INHIBITOR: RESULTS OF A FIRST-IN-MAN SAFETY AND PHARMACOKINETIC STUDY - Abstract #1375; Poster presentation; Saturday, April 25, 2009

  • PRECLINICAL PROFILES OF IDX136 AND IDX316, TWO NOVEL MACROCYCLIC HCV PROTEASE INHIBITORS - Abstract #1449; Poster presentation; Thursday, April 23, 2009

  • PRECLINICAL PHARMACOKINETIC AND SAFETY PROFILE OF IDX375, A NOVEL AND POTENT NON-NUCLEOSIDE HCV POLYMERASE INHIBITOR - Abstract #1442; Poster presentation; Thursday, April 23, 2009

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caused by hepatitis C virus. For further information about Idenix, please refer to www.idenix.com.

Forward-looking Statements

This press release contains "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward- looking statements can be identified by the use of forward-looking terminology such as "expect," "may," "plans," "anticipates," "preliminary," "will," or similar expressions, or by express or implied statements with respect to the company's clinical development programs or commercialization activities in hepatitis C, or any potential pipeline candidates and expectations with respect to future milestone payments and cash balances at the end of 2009 or beyond. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations could be affected by unexpected regulatory actions or delays; uncertainties relating to, or unsuccessful results of, clinical trials, including additional data relating to the ongoing clinical trials evaluating its product candidates; the company's ability to obtain additional funding required to conduct its research, development and commercialization activities; the company's dependence on third party collaborators, changes in the company's business plan or objectives; the ability of the company to attract and retain qualified personnel; competition in general; and the company's ability to obtain, maintain and enforce patent and other intellectual property protection for its product candidates and its discoveries. These and other risks which may impact management's expectations are described in greater detail under the caption "Risk Factors" in the company's annual report on Form 10-K for the year ended December 31, 2008 as filed with the Securities and Exchange Commission (SEC) and other filings that the company makes with the SEC.

All forward-looking statements reflect the company's expectations only as of the date of this release and should not be relied upon as reflecting the company's views, expectations or beliefs at any date subsequent to the date of this release. Idenix anticipates that subsequent events and developments may cause these views, expectations and beliefs to change. However, while Idenix may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

Idenix Pharmaceuticals' Contacts:

Media: Teri Dahlman (617) 995-9905

Investors: Amy Sullivan (617) 995-9838


'/>"/>
SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
2. Idenix to Host Conference Call Discussing Third Quarter 2007 Financial Results
3. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
4. Idenix to Host Conference Call Discussing Fourth Quarter 2007 Financial Results
5. Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL)
6. Idenix Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
7. Idenix Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
8. Idenix Pharmaceuticals to Present at the Seventh Annual Needham and Company, LLC Biotechnology and Medical Technology Conference
9. Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results
10. Idenix Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
11. Idenix to Host Conference Call Discussing Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... 4, 2016  Bayer today announced that a ... ® (regorafenib) tablets for the treatment of ... its primary endpoint of a statistically significant improvement ... the efficacy and safety of regorafenib in patients ... with sorafenib. The safety and tolerability were generally ...
(Date:5/3/2016)... India , May 3, 2016 /PRNewswire/ ... (DNA Chip (Genomics, Drug Discovery, Gene Expression) ... End user (Academics Institutes, Diagnostics Centers), Fabrication ... published by MarketsandMarkets, the market is expected ... from USD 7.63 Billion in 2015, growing ...
(Date:5/3/2016)... Boston, MA (PRWEB) , ... May 03, 2016 ... ... that facilitates accessibility to unique bioresearch materials from laboratories across the globe, ... While researchers scramble to increase the pace of research toward treatment and prevention ...
(Date:5/3/2016)... ... May 03, 2016 , ... Nashville Fertility Center ... A contingency of reproductive endocrinologists, including Dr. George Hill at Nashville ... to help them build families. , Ovation Fertility is a nationwide network of ...
Breaking Biology Technology:
(Date:3/15/2016)... March 15, 2016 Yissum Research Development ... technology-transfer company of the Hebrew University, announced today the ... sensing technology of various human biological indicators. Neteera Technologies ... million from private investors. ... the detection of electromagnetic emissions from sweat ducts, enables ...
(Date:3/11/2016)... http://www.apimages.com ) - --> http://www.apimages.com ... at AP Images ( http://www.apimages.com ) - Germany ... produce the new refugee identity cards. DERMALOG will be unveiling this ... Hanover next week.   --> ... to produce the new refugee identity cards. DERMALOG will be unveiling ...
(Date:3/10/2016)... BELL, Pa. , March 10, 2016   Unisys ... U.S. Customs and Border Protection (CBP) is testing its ... San Diego to help identify certain ... States . The test, designed to help determine the ... pedestrian environment, began in February and will run until May ...
Breaking Biology News(10 mins):